179 related articles for article (PubMed ID: 33095103)
21. Exploring Mechanisms of Communication Switching in the Hsp90-Cdc37 Regulatory Complexes with Client Kinases through Allosteric Coupling of Phosphorylation Sites: Perturbation-Based Modeling and Hierarchical Community Analysis of Residue Interaction Networks.
Stetz G; Astl L; Verkhivker GM
J Chem Theory Comput; 2020 Jul; 16(7):4706-4725. PubMed ID: 32492340
[TBL] [Abstract][Full Text] [Related]
22. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
Smith JR; Clarke PA; de Billy E; Workman P
Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
[TBL] [Abstract][Full Text] [Related]
23. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
24. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and Biological Evaluation of Celastrol Derivatives with Improved Cytotoxic Selectivity and Antitumor Activities.
Hu XL; He QW; Long H; Zhang LX; Wang R; Wang BL; Feng JH; Wang Q; Hou JQ; Zhang XQ; Ye WC; Wang H
J Nat Prod; 2021 Jul; 84(7):1954-1966. PubMed ID: 34170694
[TBL] [Abstract][Full Text] [Related]
26. Rational design of peptide inhibitors targeting HSP90-CDC37 protein-protein interaction.
Zhang Q; Yan L; Zhang Y; Zhang L; Yu J; You Q; Wang L
Future Med Chem; 2024 Jan; 16(2):125-138. PubMed ID: 38189168
[No Abstract] [Full Text] [Related]
27. Discovery of novel celastrol-triazole derivatives with Hsp90-Cdc37 disruption to induce tumor cell apoptosis.
Li N; Chen C; Zhu H; Shi Z; Sun J; Chen L
Bioorg Chem; 2021 Jun; 111():104867. PubMed ID: 33845380
[TBL] [Abstract][Full Text] [Related]
28. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
29. The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases.
Zhang X; Li S; Li Z; Cheng L; Liu Z; Wang C
Curr Drug Targets; 2022; 23(10):1023-1038. PubMed ID: 35400341
[TBL] [Abstract][Full Text] [Related]
30. Functional Role and Hierarchy of the Intermolecular Interactions in Binding of Protein Kinase Clients to the Hsp90-Cdc37 Chaperone: Structure-Based Network Modeling of Allosteric Regulation.
Stetz G; Verkhivker GM
J Chem Inf Model; 2018 Feb; 58(2):405-421. PubMed ID: 29432007
[TBL] [Abstract][Full Text] [Related]
31. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
[TBL] [Abstract][Full Text] [Related]
32. Structure of an Hsp90-Cdc37-Cdk4 complex.
Vaughan CK; Gohlke U; Sobott F; Good VM; Ali MM; Prodromou C; Robinson CV; Saibil HR; Pearl LH
Mol Cell; 2006 Sep; 23(5):697-707. PubMed ID: 16949366
[TBL] [Abstract][Full Text] [Related]
33. Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology.
Lerner Y; Sukumaran S; Chua MS; So SK; Qvit N
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35435890
[TBL] [Abstract][Full Text] [Related]
34. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity.
Cheng CJ; Liu KX; Zhang M; Shen FK; Ye LL; Wu WB; Hou XT; Hao EW; Hou YY; Bai G
Acta Pharmacol Sin; 2022 Apr; 43(4):1046-1058. PubMed ID: 34326484
[TBL] [Abstract][Full Text] [Related]
35. Atomistic simulations and network-based modeling of the Hsp90-Cdc37 chaperone binding with Cdk4 client protein: A mechanism of chaperoning kinase clients by exploiting weak spots of intrinsically dynamic kinase domains.
Czemeres J; Buse K; Verkhivker GM
PLoS One; 2017; 12(12):e0190267. PubMed ID: 29267381
[TBL] [Abstract][Full Text] [Related]
36. Dual inhibition of chaperoning process by taxifolin: molecular dynamics simulation study.
Verma S; Singh A; Mishra A
J Mol Graph Model; 2012 Jul; 37():27-38. PubMed ID: 22609743
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
Li N; Xu M; Wang B; Shi Z; Zhao Z; Tang Y; Wang X; Sun J; Chen L
J Med Chem; 2019 Dec; 62(23):10798-10815. PubMed ID: 31725288
[TBL] [Abstract][Full Text] [Related]
38. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.
Gray PJ; Stevenson MA; Calderwood SK
Cancer Res; 2007 Dec; 67(24):11942-50. PubMed ID: 18089825
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and structural studies of the interaction of Cdc37 with Hsp90.
Zhang W; Hirshberg M; McLaughlin SH; Lazar GA; Grossmann JG; Nielsen PR; Sobott F; Robinson CV; Jackson SE; Laue ED
J Mol Biol; 2004 Jul; 340(4):891-907. PubMed ID: 15223329
[TBL] [Abstract][Full Text] [Related]
40. In silico identification of potential Hsp90 inhibitors via ensemble docking, DFT and molecular dynamics simulations.
Rezvani S; Ebadi A; Razzaghi-Asl N
J Biomol Struct Dyn; 2022; 40(21):10665-10676. PubMed ID: 34286666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
